BioPharma Dive September 17, 2024
The additional cash brings the startup’s total Series A haul to over $140 million and will support a medicine it’s readying for mid-stage testing.
Dive Brief:
- Nura Bio, a private biotechnology company developing small molecule drugs for neurodegenerative conditions, has nearly doubled the size of its Series A round and named a new top executive.
- The South San Francisco startup on Tuesday announced it’s raised another $68 million in Series A funding from a group of investors led by The Column Group and including Sanofi’s venture arm. Shilpa Sambashivan, a cofounder and its chief scientist, will take over as its CEO and lead efforts to push its first drug program deeper into clinical testing.
- Nura is developing...
Today's Sponsors
Today's Sponsor